Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Ridge Biotechnologies raises additional capital, bringing its total to approximately $38M. The upsized seed round was led by Dimension Capital, alongside Sutter Hill Ventures and Overlap Holdings.
Overlap HoldingsSutter Hill VenturesDimension Capital
Description
Ridge Biotechnologies, a biotechnology company focused on enzyme and conditionally-activated drug design, announced additional investment as demand grows for its AI-designed bioconjugate therapeutics. This funding brings their total capital raised to approximately $38M. The latest round was anchored by Dimension Capital and included support from founding investors.
Company Information
Company
Ridge Biotechnologies
Location
Palo Alto, California, United States
About
Ridge Biotechnologies is a pioneering company focused on AI-enabled precision enzyme and targeted drug design. The company aims to revolutionize drug development through advanced machine learning and bioengineering techniques. Their innovative platform enables the design of therapeutics that address complex drug development challenges, promising safer and more precise medicines. Ridge Bio has launched products such as NativeLink and ProTrigger, enhancing therapeutic applications in antibody-drug conjugates.
Don't miss Ridge Biotechnologies's next move
Get an email the moment Ridge Biotechnologies raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Ridge Biotechnologies's next move
Palo AltoBiotechnologyHealth CareArtificial Intelligence